[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Through financing, Vandria will focus on the development of lead CNS mitophagy drug candidate VNA-318, which has the potential to treat cognitive impairment, dementia, Alzheimer’s, and Parkinson’s.

                          Product Name : VNA-318

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 02, 2024

                          Lead Product(s) : VNA-318

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Innosuisse

                          Deal Size : $2.9 million

                          Deal Type : Financing

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The net proceeds will be used to develop first-in-class small molecule mitophagy inducers, including VNA-318, against a novel target to rejuvenate cells and treat age-related and chronic diseases.

                          Product Name : VNA-318

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 14, 2023

                          Lead Product(s) : VNA-318

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : ND Capital

                          Deal Size : $20.6 million

                          Deal Type : Series A Financing

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).

                          Product Name : ANK-700

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 24, 2020

                          Lead Product(s) : ANK-700

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank